Latest Tyrosine kinase Stories
SAN DIEGO, Feb. 9, 2012 /PRNewswire/ -- Ambit Biosciences today announced that Michael A. Martino, Ambit's president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib, at two upcoming investor conferences at the Waldorf Astoria in New York City. 14th Annual BIO CEO & Investor Conference Presentation: 1:30 p.m. EST on Monday, February 13, 2012 Leerink Swann 2012 Global Healthcare...
SAN DIEGO, Jan. 9, 2012 /PRNewswire/ -- Ambit Biosciences Corporation today announced that the company is scheduled to present at the 30th Annual J.P. Morgan Healthcare Conference at 10 a.m. PST on Thursday, January 12, at The Westin St. Francis in San Francisco. Michael A. Martino, president and chief executive officer, will provide an overview of the company and an update about its clinical development programs, including quizartinib. About Quizartinib Quizartinib, formerly...
Cancer cells tend to take up more glucose than healthy cells, and researchers are increasingly interested in exploiting this tendency with drugs that target cancer cells' altered metabolism. Cancer cells' sugar cravings arise partly because they turn off their mitochondria, power sources that burn glucose efficiently, in favor of a more inefficient mode of using glucose. They benefit because the byproducts can be used as building blocks for fast-growing cells. Scientists at Winship...
SUNNYVALE, Calif., Dec. 19, 2011 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer and immune mediated diseases, announced today issue notification from the United States Patent & Trademark Office (USPTO, www.uspto.gov) of a patent entitled "Inhibitors of Bruton's Tyrosine Kinase" and specifically claiming "an inhibited tyrosine kinase comprising...
Novel observation may help explain resistance to targeted therapies A small percentage of the deadly brain tumors called glioblastomas, which usually resist treatment with drugs targeting mutations in cell-growth genes, appears to contain extra copies of two or three of these genes at the same time. The surprising discovery by a Massachusetts General Hospital (MGH)-based research team has major implications for the understanding of tumor biology – including the evolution of tumor cell...
Some cancers can be effectively treated with drugs inhibiting proteins known as receptor tyrosine kinases, but not those cancers caused by mutations in the KRAS gene. A team of researchers led by Jeffrey Engelman, at Massachusetts General Hospital Cancer Center, Boston, has now identified a potential way to effectively use receptor tyrosine kinases inhibitors to treat individuals with KRAS mutant colorectal cancers — combine them with inhibitors of the MEK/ERK signaling pathway. In cases...
Prediction of over 30 million human kinase-substrate interactions now available at PhosphoNET website VANCOUVER, BC, Feb. 23 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world-leader in molecular intelligence research, announced another major expansion in its PhosphoNET KnowledgeBase (www.phosphonet.ca) for the study of cell communication systems. This open access, online resource for the scientific community now features data on over 93,000 experimentally-confirmed human...
In analyzing the molecular sensor for the plant growth hormone brassinolide, researchers at the Salk Institute for Biological Studies discovered that although plants took an evolutionary path different from their animal cousins, they arrived at similar solutions to a common problem: How to reliably receive and process incoming signals.The team's findings, published in the February 1, 2011 issue of Genes and Development, revealed that so-called tyrosine phosphorylation"”used as an...
ROCKVILLE, Md., Nov. 9, 2010 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today announced presentations for its Phase 2 oncology drug candidate, ENMD-2076. Data for the ENMD-2076 Phase 1 studies in multiple myeloma and leukemia will be presented by EntreMed investigators at the 2010 Annual Meeting of the American Society of Hematology (ASH) to be held December 4-7 at the Orange County...
The interaction of enzymes "“ especially the tyrosine kinases called Src and inducible nitric oxide synthase "“ plays an important role in the growth of non-small cell lung cancers, the most common form of this deadly disease in the United States, said researchers from Baylor College of Medicine in a report in the Journal of Biological Chemistry.Such cancers require activation of the epidermal growth factor receptor, said Dr. Tony Eissa, professor of medicine "“ pulmonary, at BCM....
